Page last updated: 2024-11-01

nicardipine and Limited Scleroderma

nicardipine has been researched along with Limited Scleroderma in 1 studies

Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.
nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.
2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lichtenstein, SJ1
Herring, MJ1
Baxi, PV1
Abrams, RI1
Korbet, SM1

Other Studies

1 other study available for nicardipine and Limited Scleroderma

ArticleYear
Without Warning: Scleroderma Renal Crisis.
    The American journal of medicine, 2019, Volume: 132, Issue:2

    Topics: Acute Kidney Injury; Amlodipine; Antihypertensive Agents; Humans; Hypertension; Labetalol; Lisinopri

2019